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Solitary fibrous tumors of the pleura: a clinical-pathological 
characterization emphasizing changes in lung function 
Abstract 
Solitary fibrous tumors of the pleura (SFTP) represent less than 5% of all pleural tumors with a higher susceptibility for men in the 
sixth and seventh decades of life. Imaging and histopathological analyses indicate that these tumors have an unpredictable clinical 
course since larger tumors are often associated with malignancy; however, this assumption is not universal. In addition, there are 
no systematic descriptions of lung function in either the basal or post-surgical scenarios of SFTP patients. We describe a series 
of 3 patients between 4th and 5th decade of life with a benign histopathological SFTP without local recurrence in their follow-up. 
We also analyzed changes in lung function, emphasizing possible associations with clinical recovery.
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Introduction
Since the initial categorization of solitary 
fibrous tumors of the pleura (SFTP) [1], the 
literature worldwide contains descriptions of 
over 800 cases, highlighting clinical and his-
topathological aspects, tumor dimensions and 
trans-operatory eventualities. Currently, it is 
estimated that SFTP has an incidence rate of 
2.8 cases per 100,000 registered hospital pa-
tients [2]. Solitary fibrous tumors of the pleura 
can affect individuals of all ages; however, it 
is most often reported in the sixth or seventh 
decade of life. Men and women are equally af-
fected without relation to race. Clinically, the 
range of expression varies from asymptomatic 
(incidental findings) to such frequent manifes-
tations as thoracic pain, coughing and dyspnea 
[3–4]. We found no descriptions of lung func-
tion to determine to what degree those changes 
are representative of the disease’s clinical im-
pact [5]. Accordingly, we sought to characterize 
the clinical and pathological behavior of the 
population treated at our hospital in the last 
five years, emphasizing lung function changes.
Case 1
A 37-year-old female with a history of well- 
-controlled asthma and otherwise healthy, without 
smoking, use of biomass fuels, asbestos or other 
dust exposures sought medical attention after 
2 years of progressive moderate-to-severe dyspnea 
(MRC 3). She also complained about malaise, 
a sensation of fullness in her right hemithorax, 
without weight loss. On physical examination, du-
lled percussion was found in the right hemithorax. 
A computed tomography (CT) scan of the chest 
revealed a large-volume tumor adhered to the vi-
sceral and parietal pleura (Figure 1A). Pre-surgical 
spirometry revealed an FVC of 0.89 L (30%).
Once informed consent was signed, surgery 
was performed to resect the tumor that measu-
red 20 × 25 cm. Total blood loss during surge-
ry was 2000 cc. The pathology report confirmed 
an SFTP and less than one mitosis per high-po-
wer field (HPF) (Figure 2A). During follow-up 
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Figure 1. A. Axial chest CT scan showed right pleural tumor 
involving middle and inferior lobes. B. Axial chest CT scan showed 
a large heterogeneous tumor in left hemithorax with displacement 
of mediastinal vascular structures. C. Axial chest CT scan, sho-
wed a large mass with significant displacement of mediastinal 
structures
Figure 2. A. Fusiform cells mixed with collagen bundles (40×). B. 
Vascular pattern on deer antlers (10×). C. Collagen bundles with 
myxoid appearance areas (10×)
(6 months), lung function (Table 1) showed si-
gnificant improvement of FVC (2.83 L, 93% pre-
dicted). After 21 months of surgery, the patient 
is respiratory asymptomatic and without signs of 
disease recurrence.
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Table 1. Differences of baseline and postoperative pulmonary function
Variable Baseline Postoperative Change 
(postoperative-baseline)
Case 1
FVC (%p) 30 93 218%
FVC (Lts) 0.89 2.83 1.94 Lts
FEV1 (%p) 39 93 222 %
FEV1 (Lts) 0.73 2.35 1.62 Lts
FEV1/FVC (%) 83 83
Case 2
FVC (%p) 38 71 87%
FVC (Lts) 1.57 3.02 1.45 Lts.
FEV1 (%p) 40 81 103 %
FEV1 (Lts) 1.32 2.73 1.41 Lts
FEV1/FVC (%) 84 90
Case 3
FVC (%p) 24 67 179%
FVC (Lts) 0.68 1.92 1.24 Lts
FEV1 (%p) 22 69 214%
FEV1 (Lts) 0.53 1.62 1.09 Lts
FEV1/FVC (%) 78 84
FVC — forced vital capacity; FEV1 — forced expiratory volume in 1st second of expiration
Case 2
A  43-year-old male without smoking or 
exposure to dust or biomass fuels sought medical 
attention after a year of progressive mild-to-mode-
rate dyspnea (MRC 2). He also complained about 
intermittent oppressive chest pain. The physical 
examination revealed dulled percussion in the left 
hemithorax, otherwise normal. The chest CT scan 
showed a highly vascularized tumor measuring 
13 × 18 cm (Figure 1B). Baseline lung function 
showed an FVC of 1.57 L (38% predicted).
A biopsy was taken following written infor-
med consent due to the vascular findings on CT. 
The pathology analysis reported the presence of 
vascularized mesenchymal neoplasia without 
atypia. Surgery was performed to resect the tumor. 
The size was 15 × 15 cm and total blood loss 
was 800 cc. Pathology confirmed an SFTP with 
less than 2 mitoses per HPF (Figure 2B). After 
6 months, spirometry testing showed an increase 
in FVC to 3.02 L (71% predicted). After 11 months 
of surgery, the patient is alive without recurrence.
Case 3
A  37-year-old otherwise healthy female 
sought medical attention after 3 years with pro-
gressive dyspnea (MRC) accompanied by weight 
loss (13 kg) and intermittent fever. The chest CT 
scan confirmed a tumor in the left hemithorax that 
displaced the mediastinal structures and pleural 
effusion (Figure 1C). 
Baseline spirometry showed an FVC of 
0.68 L (24%). After informed consent was signed, 
surgery was performed and a tumor of 45 × 35 cm 
was resected from the left hemithorax with a total 
blood loss of 1200 cc (Figure 2C). Pathology con-
firmed the existence of SFTP without evidence 
of malignancy and less than 1 mitosis per HPF. 
During follow-up, FVC increased to 1.92 L 
(67%). Currently; the patient has a disease-free 
survival of 7 months with no recurrence.
Discussion
The findings considered to be relevant in 
these clinical cases are as follows: a) age at the 
time of diagnosis; b) the disease-free survival; 
c) the size of the SFTP; and d) the improvement 
in lung function.
Despite SFTP being more prevalent between 
6th and 7th decade of life, it can affect young pe-
ople. Indeed, previous reports have described 
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a range of ages between 34 and 83 years [6]. In 
a Hispanic case-series, we have demonstrated 
that around 20% of patients are under 50 years 
of age at the time of diagnosis [3–4]. Virtually all 
published reports do not evaluate possible hypo-
theses concerning the age at diagnosis or gender 
predominance.
At the time of writing the present manuscript, 
our cases showed a mean disease-free survival of 
13 months without signs of recurrence or mali-
gnancy. Previous reports have estimated a disease- 
-free survival in a  Hispanic population up to 
48.5 months [3]. There is scarce information regar-
ding surveillance after resection in patients with 
SFTP. Tapias et al., developed a scoring system ba-
sed on pathology findings: a) parietal pleura origin; 
b) sessile morphology; c) size of tumor > 10 cm; 
d) presence of hypercellularity; e) necrosis and 
mitotic activity (> 4/HPF). Recurrence free-survi-
val was 100% up to 15 years with a score < 3 [7]. 
In addition, You et al. have used CT scan findin-
gs to differentiate benign from malignant SFTP, 
showing that, in contrast to benign tumors, mali-
gnant tumors: a) were greater in size; b) had a hi-
gher percentage rate of inhomogeneous density; 
c) had increased tumor vascularity; and d) sho-
wed pleural effusions. Based on these reports, it is 
suggested that surveillance should be considered 
up to 24 months, accompanied by imaging eva-
luations — CT scans — every six months [8, 9].
Regarding the size, most cases of SFTP are 
described as tumors < 10 cm incidentally disco-
vered in asymptomatic patients during medical 
evaluations that include a chest x-ray [10]. It is 
thought that the larger the tumor the higher the 
risk of malignancy [7]. Nonetheless, Harrison et al. 
reported a mean size for malignant SFTP of 12 cm 
[6]. The dimensions of the SFTP presented herein 
are not the ones commonly reported previously, 
and none were associated with malignancy. We can 
conclude that SFTP might have “an unpredictable” 
behavior if clinicians consider only the size. SFTP 
larger than 18 cm, or that occupy at least 40% of 
the total volume of a hemithorax, are referred to 
as “Giant SFTP”. They represent a challenge for 
surgical resection due to less anatomical exposure, 
greater risk of blood loss, and significant adheren-
ces [11]. To the best of our knowledge, in Mexico 
and Latin America, there is only one case report 
on SFTP that have dimensions up to 40 cm [4]. 
One of our cases is, to our knowledge, the largest 
tumor resected (45 cm) and showed benign beha-
vior without vascular complications.
Finally, regarding lung function in SFTP pa-
tients, we were unable to find any detailed analy-
sis or reliable description to compare our findings. 
However, we did explore possible explanations that 
could have effects after surgical resection of SFTP. 
Whenever a tumor occupies a volume in the affec-
ted hemithorax, respiratory mechanics and lung 
compliance become compromised. For example, an 
increase in SFTP volume decreases lung volume, 
resulting in a rise in airway resistance. These phy-
siological changes ultimately increase the driving 
pressure needed to generate a given tidal volume. 
This can be compensated through an augmented 
inspiratory muscle effort and alterations in bre-
athing patterns (rapid shallow breathing), but this 
likely comes at the expense of increased dyspnea. 
Abnormalities in the pleural and intratho-
racic pressure become relevant as the main 
components of the transmural pressure, which 
has an important influence on many aspects 
of pulmonary function. Once the tumor volu-
me increases, the transmural pressure gradient 
decreases, compromising ventilation/perfusion 
ratios and therefore gas exchange, another physio- 
-pathological explanation of dyspnea [12].
As this condition worsens, accessory muscles 
of inspiration are activated generating a more pro-
nounced decrease in the intrapleural and alveolar 
pressure that enables the movement of airflow. 
As a consequence, energy expenditure increases, 
triggering the appearance of symptoms such as 
chest pain and fatigue [13]. 
Regarding lung function, baseline measure-
ments in our patients suggest a severe restrictive 
ventilatory pattern (FVC below 40% predicted); 
however, during post-surgical surveillance of 
at least 6 months, we observed a  tremendous 
functional recovery showing a mild-to-moderate 
restrictive pattern (FVC above 60% predicted). 
Numerically, the absolute change was two-fold 
higher than baseline measurements. Collec-
tively, these changes can be explained by the 
post-surgical improvements in compliance of 
the pulmonary tissue, thoracic cage, and airway 
resistance, given that pulmonary volume is com-
promised proportionally to tumor size [12, 13]. 
We acknowledge that total lung capacity was 
not measured in our patients in order to confirm 
a  restrictive ventilatory pattern. If available, 
plethysmography would provide additional 
insight into changes in pulmonary function 
following surgery. However, in contrast to spiro-
metry, plethysmography is not always available 
in routine clinical practice.
Based on the current analysis, we consider 
it extremely important to continue the follow-
-up of SFTP patients by measuring pulmonary 
Heron Mendez-Sanchez et al., Solitary fibrous tumors of the pleura
251www.journals.viamedica.pl
function and performing CT scans, as these two 
approaches will provide an objective evaluation 
of patients’ functional and structural changes 
following surgery.
Conclusion
SFTP are rare pleural neoplasms with a final 
diagnosis being obtained after surgical resection. 
Lung function should be routinely measured 
before surgery since we have shown that these 
patients can have a restrictive ventilatory pattern 
that improves after surgery.
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